INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 196 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $29 | -100.0% | 64,600 | -15.0% | 0.00% | -50.0% |
Q3 2022 | $92,000 | +29.6% | 76,000 | +190.1% | 0.01% | +50.0% |
Q2 2022 | $71,000 | -57.7% | 26,200 | -40.2% | 0.00% | -42.9% |
Q1 2022 | $168,000 | -42.5% | 43,800 | -41.4% | 0.01% | -12.5% |
Q4 2021 | $292,000 | +43.1% | 74,800 | +39.3% | 0.01% | +14.3% |
Q3 2021 | $204,000 | +17.9% | 53,700 | -0.9% | 0.01% | +16.7% |
Q2 2021 | $173,000 | +23.6% | 54,200 | +43.0% | 0.01% | -25.0% |
Q1 2021 | $140,000 | +723.5% | 37,900 | +103.8% | 0.01% | – |
Q4 2020 | $17,000 | -96.1% | 18,600 | -89.7% | 0.00% | -100.0% |
Q4 2019 | $437,000 | -91.2% | 180,600 | -11.0% | 0.02% | -94.1% |
Q3 2019 | $4,957,000 | +152.9% | 202,857 | +122.5% | 0.40% | +170.0% |
Q2 2019 | $1,960,000 | +8809.1% | 91,162 | -17.7% | 0.15% | +7400.0% |
Q1 2019 | $22,000 | -98.5% | 110,800 | -15.7% | 0.00% | -97.3% |
Q1 2018 | $1,496,000 | +24833.3% | 131,380 | +537.8% | 0.08% | – |
Q3 2017 | $6,000 | -98.4% | 20,600 | -21.7% | 0.00% | -100.0% |
Q2 2016 | $380,000 | – | 26,300 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |